Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies

被引:2
|
作者
DeRosier, Frederick [1 ]
Hibbs, Cody [1 ]
Alessi, Kaitlyn [2 ]
Padda, Inderbir [3 ]
Rodriguez, Jeanette [4 ]
Pradeep, Swati [5 ]
Parmar, Mayur S. [1 ]
机构
[1] Nova Southeastern Univ, Dr Kiran C Patel Coll Osteopath Med, Dept Fdn Sci, Clearwater, FL 33759 USA
[2] Univ Florida, Dept Family Med, Gainesville, FL USA
[3] Richmond Univ, Med Ctr, Dept Internal Med, Staten Isl, NY USA
[4] Nova Southeastern Univ, Dr Kiran C Patel Coll Osteopath Med, Dept Family Med, Clearwater, FL USA
[5] UTHlth Houston Neurosci Neurol Texas Med Ctr, Dept Movement Disorders, Houston, TX USA
来源
DM DISEASE-A-MONTH | 2024年 / 70卷 / 08期
关键词
Progressive supranuclear palsy; Pathophysiology; Clinical diagnosis; Imaging; Treatment and managment; Emerging therapies; PARKINSONS-DISEASE; TAU; PATHOLOGY; DISORDERS; COGNITION; SURVIVAL; ATROPHY; HEALTH; SPECT; RISK;
D O I
10.1016/j.disamonth.2024.101753
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by the accumulation of 4R-tau protein aggregates in various brain regions. PSP leads to neuronal loss, gliosis, and tau-positive inclusions, such as neurofibrillary tangles, tufted astrocytes, and coiled bodies. These pathological changes mainly affect the brainstem and the basal ganglia, resulting in distinctive MRI features, such as the hummingbird and morning glory signs. PSP shows clinical heterogeneity and presents as different phenotypes, the most classical of which is Richardson's syndrome (PSP-RS). The region of involvement and the mode of atrophy spread can further distinguish subtypes of PSP. PSP patients can experience various signs and symptoms, such as postural instability, supranuclear ophthalmoplegia, low amplitude fast finger tapping, and irregular sleep patterns. The most common symptoms of PSP are postural instability, falls, vertical gaze palsy, bradykinesia, and cognitive impairment. These features often overlap with those of Parkinson's disease (PD) and other Parkinsonian syndromes, making the diagnosis challenging. PSP is an essential clinical topic to research because it is a devastating and incurable disease. However, there are still many gaps in knowledge about its pathophysiology, diagnosis, and treatment. Several clinical trials are underway to test noveltherapies that target tau in various ways, such as modulating its post-translational modifications, stabilizing its interaction with microtubules, or enhancing its clearance by immunotherapy. These approaches may offer new hope for slowing down the progression of PSP. In this review, we aim to provide an overview of the current knowledge on PSP, from its pathogenesis to its management. We also discuss the latest advances and future directions in PSP research. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy
    Seki, Morinobu
    Seppi, Klaus
    Mueller, Christoph
    Potrusil, Thomas
    Goebel, Georg
    Reiter, Eva
    Nocker, Michael
    Steiger, Ruth
    Wildauer, Matthias
    Gizewski, Elke R.
    Wenning, Gregor K.
    Poewe, Werner
    Scherfler, Christoph
    PARKINSONISM & RELATED DISORDERS, 2018, 49 : 81 - 87
  • [32] Diagnostic potential of automated tractography in progressive supranuclear palsy variants
    Potrusil, Thomas
    Krismer, Florian
    Beliveau, Vincent
    Seppi, Klaus
    Mueller, Christoph
    Troger, Felix
    Goebel, Georg
    Steiger, Ruth
    Gizewski, Elke R.
    Poewe, Werner
    Scherfler, Christoph
    PARKINSONISM & RELATED DISORDERS, 2020, 72 : 65 - 71
  • [33] Progressive supranuclear palsy: current approach and challenges to diagnosis and treatment
    Carpentier, Ariane Veilleux
    McFarland, Nikolaus R.
    CURRENT OPINION IN NEUROLOGY, 2023, 36 (04) : 309 - 316
  • [34] Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy
    Morris, HR
    Gibb, G
    Katzenschlager, R
    Wood, NW
    Hanger, DP
    Strand, C
    Lashley, T
    Daniel, SE
    Lees, AJ
    Anderton, BH
    Revesz, T
    BRAIN, 2002, 125 : 969 - 975
  • [35] Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy
    Wiblin, Louise
    Lee, Mark
    Burn, David
    PARKINSONISM & RELATED DISORDERS, 2017, 34 : 7 - 14
  • [36] Diversified psychiatric presentation in a case of progressive supranuclear palsy
    Chiu, Yu-Wen
    Lee, Shwu-Hua
    Yeh, Tu-Hsueh
    JOURNAL OF CLINICAL GERONTOLOGY & GERIATRICS, 2016, 7 (04) : 164 - 167
  • [37] Progressive Supranuclear Palsy Challenges and Considerations for Care Transitions
    Wodwaski, Nadine
    CRITICAL CARE NURSING CLINICS OF NORTH AMERICA, 2023, 35 (04) : 393 - 401
  • [38] The diagnosis of progressive supranuclear palsy: current opinions and challenges
    Ali, Farwa
    Josephs, Keith
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2018, 18 (07) : 603 - 616
  • [39] Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect
    Nasri, Amina
    Sghaier, Ikram
    Neji, Anis
    Gharbi, Alya
    Abida, Youssef
    Mrabet, Saloua
    Gargouri, Amina
    Ben Djebara, Mouna
    Kacem, Imen
    Gouider, Riadh
    JOURNAL OF MOVEMENT DISORDERS, 2024, 17 (02) : 158 - 170
  • [40] Update on the Diagnosis and Management of Progressive Supranuclear Palsy
    Garrido A.
    Vilas D.
    Tolosa E.
    Current Geriatrics Reports, 2016, 5 (2) : 85 - 94